Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

During his second day of confirmation hearings, Robert F. Kennedy Jr. declined to disavow comments he had made disparaging ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

Robert F. Kennedy Jr. also disclosed that he had reached at least one settlement agreement with a company or individual that has accused him of “misconduct or inappropriate behavior.” ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Getting the HPV vaccine in early adolescence may lower the risk of HPV-related cancers before exposure occurs. Learn about ...

Facing intense scrutiny from senators over his potential profit from vaccine lawsuits while serving as the nation's health ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...